Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis

  • ID: 2735002
  • January 2014
  • Region: Global
  • 347 Pages
  • La Merie Publishing
1 of 4


  • AbbVie
  • Auven Therapeutics
  • Daiichi Sankyo
  • ImmunoGen
  • Oncomatrix
  • Seattle Genetics
  • MORE

The report entitled 'Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis' is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.

The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • AbbVie
  • Auven Therapeutics
  • Daiichi Sankyo
  • ImmunoGen
  • Oncomatrix
  • Seattle Genetics
  • MORE

0 Abbreviations

1 Executive Summary

2 Introduction and Overview of the Report

3 Antibody-Drug Conjugates: Pipeline Description and Analysis

3.1 ADC Pipeline overview and definitions
3.2 Targeting moieties in ADCs and Immunoconjugates
3.3 Drugs & linkers in ADCs and Immunoconjugates
3.4 Targets in ADCs and indications
3.5 Companies clinically developing ADCs
3.6 Clinical success and attrition rates of ADCs

4 Stakeholders in Antibody-Drug Conjugates and Immunoconjugates

4.1 Development companies
4.1.1 Big Pharma with ADCs or Immunoconjugates
4.1.2 Pharma and Biotech Companies with ADCs or Immunoconjugates
4.2 Technology companies
4.2.1 Integrated ADC technology and development companies
4.2.2 Companies with target discovery
4.2.3 Companies with alterntive targeting moieties
4.2.4 Site-specific conjugation technology companies
4.2.5 Companies with polymeric/nanoparticle payload carriers
4.2.6 Companies with new payloads
4.3 Manufacturing companies

5 ADC Technologies

5.1 Targets for ADC
5.2 Antibodies for ADCs
5.3 Linkers and conjugation strategies
5.4 Drugs as payload

6 Business with Antibody-Drug Conjugates

6.1 Commercial valuation of ADC technologies and products
6.1.1 ADC product sales
6.1.2 Market capitalization of ADC companies
6.1.3 Value of Initial Public Offerings (IPOs) of ADC biotech companies
6.1.4 Venture capital and private equity financing of ADC technology and product companies
6.1.5 Acquisitions of ADC technology companies
6.1.6 Financial deal terms of agreements between biotech and pharma
6.1.7 ADC collaborations biotech - biotech
6.1.8 ADC infrastructure investments

6.2 Business opportunities with antibody-drug conjugates
6.2.1 Therapeutic window
6.2.2 Drug resistance
6.2.3 Druggable targets
6.2.4 Non-cancer indications
6.2.5 Manufacturing of ADCs
6.2.6 Finance industry

7 ADC & Immunoconjugate Company Profiles

7.1 Development Companies
7.2 Technology Companies
7.3 Contract Manufacturing Companies

8 References

9 Tables
Table 1 Overall pipeline of Antibody-Drug Conjugates and Immunoconjugates
Table 2: Targeting moieties used in ADCs and Immunoconjugates
Table 3: Drugs used in ADCs
Table 4: Other and novel payloads used in ADCs and Immunoconjugates
Table 5: Stable and cleavable linkers for ADCs with auristatins or maytansinoids
Table 6: Targets of ADCs with linkers, drugs, indications and stage
Table 7: ADCs against CD22
Table 9: ADCs against Her2
Table 9: ADCs against CD19
Table 10: ADCs against PSMA
Table 11: ADCs against EGFR / EGFRvIII
Table 12: ADCs against MUC1
Table 13: ADCs against CD37
Table 14: ADCs against CD70
Table 15: ADCs against CD20
Table 16: Companies clinically developing ADCs and related technologies
Table 17: Reasons for Discontinuation of Clinical Stage Antibody-Drug Conjugates
Table 18: Comparison of reasons for failure between ADCs and naked antibodies
Table 19: Overview of ADC & Immunoconjugate activities of major pharma & biotech companies
Table 20: Synopsis of Big Pharma‘s ADC activities
Table 21: Synopsis of pharma and biotech development companies‘ ADC activities
Table 22: Synposis of integrated ADC technology and development companies
Table 23: Synopsis of companies with target discovery
Table 24: Synopsis of companies with alterntive targeting moieties
Table 25: Synopsis of site-specific conjugation technology companies
Table 26: Synopsis of companies with polymeric/nanoparticle payload carriers
Table 27: Synopsis of companies with new payloads
Table 28: Overview of CMOs for ADCs
Table 29: Synopsis of ADC CMOs
Table 30: Market capitalization of Seattle Genetics and ImmunoGen 2011-2014
Table 31: Financing of ADC technology and product companies
Table 32: Financial terms of ADC technology deals biotech – pharma 2011-2014
Table 33: R&D collaborations between biotech companies


I: Competitor Analysis

Adcetris Pipeline
ADCs with Auristatin Derivatives
ADCs with Pyrrolobenzodiazepine (PBD) Derivatives
Kadcyla Pipeline
ADCs with Maytansine (DM) Derivatives
ADCs with Irinotecan Derivatives
ADCs with Calicheamicin Derivatives
ADCs with Doxorubicin as Payload
ADCs with Duocarmycin Derivatives
ADCs with Novel Payloads
ADCs with Not-Disclosed Payloads
ADCs with Novel Conjugation Systems
ADCs with Alternative Antibody Formats
Immunoconjugates with Peptide-based Targeting Moiety
Immunoconjugates with Protein-based Targeting Moiety
Immunoconjugates with Small Molecule-based Targeting Moiety
ADCs and Immunoconjugates in Non-Cancer Indications

II: Agreements

R&D Collaboration Agreements biotech – pharma
R&D Collaboration Agreements biotech - biotech
Collaboration Agreements CMO - CMO
R&D Licensing Agreements biotech - pharma
R&D Licensing Agreements biotech - biotech
Merger & Acquisition Agreements

Note: Product cover images may vary from those shown
3 of 4

- Abbott Contract Manufacturing
- AbbVie
- AbGenomics
- Ablynx
- ACES Pharma
- ADC Therapeutics
- Adcanced Proteome Therapeutics
- Aeterna Zentaris
- Affinicon
- Albany Molecular Research Inc (AMRI)
- Allozyne
- Ambrx
- Amgen
- Amunix
- Arrowhead Research
- Astellas Pharma
- AstraZeneca
- Auven Therapeutics
- Baxter BioPharma Solutions
- Bayer HealthCare Pharmaceuticals
- BIND Therapeutics
- Biotecnol
- Biotest
- Bristol-Myers Squibb
- BSP Pharmaceuticals
- Carbogen Amcis
- Catalent Biologics
- Celgene
- Celldex Therapeutics
- Centrose
- Coldstream Laboratories
- Concortis Biosystems
- CytomX
- Daiichi Sankyo
- Eli Lilly
- Endo Pharmaceuticals
- Esperance Pharmaceuticals
- Evonik Industries
- f-star
- Fujifilm Diosynth Biotechnologies
- Genmab
- GlaxoSmithKline
- Glykos
- Goodwin Biotechnology
- Wilex (Heidelberg Pharma)
- Helix Biopharma
- Heraeus
- Igenica
- Immune Pharmaceuticals
- ImmunoGen
- Immunomedics
- Innate Pharma
- Intellect Neurosciences
- Janssen Research & Development
- Lonza
- Macrogenics
- Meditope Biosciences
- Menarini
- Merck
- Mersana Therapeutics
- Molecular Partners
- Nerviano Medical Sciences
- Novartis
- Novasep
- Oncomatrix
- Oxford BioTherapeutics
- Pfizer
- Philogen
- Photobiotics
- Phylogica
- Pierre Fabre Group
- Pierre Fabre Medicament Production
- Piramal
- Polytherics
- Progenics Pharmaceuticals
- Quanta Biodesign
- Redwood Biodesign
- Roche
- Sanofi
- Seattle Genetics
- Serina Therapeutics
- Shire
- Sigma Aldrich SAFC
- Sorrento Therapeutics
- Spirogen
- Stem CentRx
- Sutro Biopharma
- SynAffix
- Synthon Biopharmaceuticals
- Takeda Pharmaceutical
- The Chemistry Research Solution
- TUBE Pharma
- University of California San Diego
- WuXi PharmaTech
- Zhejiang Medicine
- Zymeworks

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.


If you have a more general question about our products please try our



Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)